Focused On-demand Library for tRNA N(3)-methylcytidine methyltransferase METTL2B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q6P1Q9

UPID:

MET2B_HUMAN

Alternative names:

Methyltransferase-like protein 2B

Alternative UPACC:

Q6P1Q9; B4DZ68; Q0IJ54; Q3B7J1

Background:

tRNA N(3)-methylcytidine methyltransferase METTL2B, also known as Methyltransferase-like protein 2B, plays a crucial role in post-transcriptional modification. It specifically mediates N(3)-methylcytidine modification of residue 32 in the tRNA anticodon loop of tRNA(Thr)(UGU) and tRNA(Arg)(CCU), a process vital for the accuracy and efficiency of protein synthesis.

Therapeutic significance:

Understanding the role of tRNA N(3)-methylcytidine methyltransferase METTL2B could open doors to potential therapeutic strategies. Its precise function in tRNA modification suggests a foundational role in protein synthesis, offering a novel target for drug discovery efforts aimed at treating diseases with underlying genetic and protein synthesis disorders.